Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;30(1):93-9.
doi: 10.1007/s00774-011-0290-8. Epub 2011 Jul 8.

Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia

Affiliations

Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia

Yasuo Imanishi et al. J Bone Miner Metab. 2012 Jan.

Abstract

Oncogenic osteomalacia (OOM), or tumor-induced osteomalacia, is a rare disease characterized by renal phosphate wasting and osteomalacia. It arises due to the secretion of fibroblast growth factor 23 (FGF-23) from causative tumors. Matrix extracellular phosphoglycoprotein (MEPE) is predominantly expressed in odontoblasts, osteoblasts, and osteocytes. Although the presence of MEPE mRNA has been reported in some OOM tumors, little is known about the prevalence of MEPE expression in OOM tumors. In this study, the expression of MEPE and FGF-23 in OOM tumors was investigated at the transcriptional and translational levels. Eleven causative OOM tumors were analyzed by quantitative real-time reverse transcription-polymerase chain reaction and immunohistochemistry for MEPE and FGF-23 expression. Hemangiopericytomas and giant cell tumors, pathological diagnoses that are common in cases of OOM, were obtained from non-osteomalacic patients and analyzed as controls. The gene expression level of FGF23 and MEPE in OOM tumors was 10(4)- and 10(5)-times higher, respectively, than in non-OOM tumors. Immunohistochemical staining revealed that FGF-23 protein was expressed in all OOM tumors, and MEPE was expressed in 10 out of 11 OOM tumors. Thus, MEPE expression was common in OOM tumors, similar to FGF-23. These results indicate that, in addition to the hypophosphatemic effects of FGF-23, MEPE or the MEPE-derived acidic serine aspartate-rich MEPE-associated motif peptide may contribute to decreased bone mineralization in OOM patients.

PubMed Disclaimer

References

    1. Calcif Tissue Int. 2010 Jan;86(1):42-6 - PubMed
    1. J Clin Endocrinol Metab. 2002 Nov;87(11):4957-60 - PubMed
    1. Kidney Int. 2004 May;65(5):1943-6 - PubMed
    1. J Bone Miner Res. 2008 Oct;23(10):1638-49 - PubMed
    1. Calcif Tissue Int. 2010 Jun;86(6):455-62 - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources